Originally published as JCO Early Release 10.1200/JCO.2005.06.081 on December 7 2004
Journal of Clinical Oncology, Vol 23, No 5 (February 10), 2005: pp. 1011-1027
© 2005 American Society of Clinical Oncology.
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Daniel J. Hicklin,
Lee M. Ellis
From the Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY; and Departments of Surgical Oncology and Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Address reprint requests to Daniel J. Hicklin, PhD, Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY 10014; e-mail: dan.hicklin{at}imclone.com.
New blood vessel formation (angiogenesis) is a fundamental event in the process of tumor growth and metastatic dissemination. Hence, the molecular basis of tumor angiogenesis has been of keen interest in the field of cancer research. The vascular endothelial growth factor (VEGF) pathway is well established as one of the key regulators of this process. The VEGF/VEGF-receptor axis is composed of multiple ligands and receptors with overlapping and distinct ligand-receptor binding specificities, cell-type expression, and function. Activation of the VEGF-receptor pathway triggers a network of signaling processes that promote endothelial cell growth, migration, and survival from pre-existing vasculature. In addition, VEGF mediates vessel permeability, and has been associated with malignant effusions. More recently, an important role for VEGF has emerged in mobilization of endothelial progenitor cells from the bone marrow to distant sites of neovascularization. The well-established role of VEGF in promoting tumor angiogenesis and the pathogenesis of human cancers has led to the rational design and development of agents that selectively target this pathway. Studies with various anti-VEGF/VEGF-receptor therapies have shown that these agents can potently inhibit angiogenesis and tumor growth in preclinical models. Recently, an anti-VEGF antibody (bevacizumab), when used in combination with chemotherapy, was shown to significantly improve survival and response rates in patients with metastatic colorectal cancer and thus, validate VEGF pathway inhibitors as an important new treatment modality in cancer therapy.
Supported, in part, by National Institutes of Health grants, and CA74821 and U54-CA90810 (L.M.E), the Lustgarten Foundation for Pancreatic Research (L.M.E), and the Lockton Fund for Pancreatic Cancer Research (L.M.E).
Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. P. Marin, A. R. Sanchez, and E. E. Arranz
Nasal septum perforation in a breast cancer patient treated with bevacizumab
Ann. Onc.,
November 1, 2009;
20(11):
1901 - 1902.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C Caires, J. de Avila, and D. J McLean
Vascular endothelial growth factor regulates germ cell survival during establishment of spermatogenesis in the bovine testis
Reproduction,
October 1, 2009;
138(4):
667 - 677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Di Lorenzo, G. Carteni, R. Autorino, G. Bruni, M. Tudini, M. Rizzo, M. Aieta, A. Gonnella, P. Rescigno, S. Perdona, et al.
Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
J. Clin. Oncol.,
September 20, 2009;
27(27):
4469 - 4474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Folkins, Y. Shaked, S. Man, T. Tang, C. R. Lee, Z. Zhu, R. M. Hoffman, and R. S. Kerbel
Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1
Cancer Res.,
September 15, 2009;
69(18):
7243 - 7251.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dadiani, D. Seger, T. Kreizman, D. Badikhi, R. Margalit, R. Eilam, and H. Degani
Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor {alpha} and c-Myc
Endocr. Relat. Cancer,
September 1, 2009;
16(3):
819 - 834.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grothey
Review: Medical treatment of advanced colorectal cancer in 2009
Therapeutic Advances in Medical Oncology,
September 1, 2009;
1(2):
55 - 68.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Wozniak and S. M. Gadgeel
Review: Adjuvant therapy for resected non-small cell lung cancer
Therapeutic Advances in Medical Oncology,
September 1, 2009;
1(2):
109 - 118.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Morelli, A. M. Brown, T. M. Pitts, J. J. Tentler, F. Ciardiello, A. Ryan, J. M. Jurgensmeier, and S. G. Eckhardt
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines
Mol. Cancer Ther.,
September 1, 2009;
8(9):
2546 - 2558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. Schneider, M. Radovich, and K. D. Miller
The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer
Clin. Cancer Res.,
September 1, 2009;
15(17):
5297 - 5302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Lucio-Eterovic, Y. Piao, and J. F. de Groot
Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy
Clin. Cancer Res.,
July 15, 2009;
15(14):
4589 - 4599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Schettino, M. A. Bareschino, A. Rossi, P. Maione, V. Castaldo, N. Mazzeo, P. C. Sacco, M. L. Ferrara, G. Palazzolo, F. Ciardiello, et al.
Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer
Therapeutic Advances in Medical Oncology,
July 1, 2009;
1(1):
5 - 13.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
W. B. Pope, H. J. Kim, J. Huo, J. Alger, M. S. Brown, D. Gjertson, V. Sai, J. R. Young, L. Tekchandani, T. Cloughesy, et al.
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Radiology,
July 1, 2009;
252(1):
182 - 189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bhargava
VEGF kinase inhibitors: how do they cause hypertension?
Am J Physiol Regulatory Integrative Comp Physiol,
July 1, 2009;
297(1):
R1 - R5.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Ichihara, K. Ohashi, N. Takigawa, M. Osawa, A. Ogino, M. Tanimoto, and K. Kiura
Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo
Cancer Res.,
June 15, 2009;
69(12):
5091 - 5098.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. TONRA, E. CORCORAN, D. S. DEEVI, P. STEINER, J. KEARNEY, H. LI, D. L. LUDWIG, Z. ZHU, L. WITTE, D. SURGULADZE, et al.
Prioritization of EGFR/IGF-IR/VEGFR2 Combination Targeted Therapies Utilizing Cancer Models
Anticancer Res,
June 1, 2009;
29(6):
1999 - 2007.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. O. Hanrahan, A. J. Ryan, H. Mann, S. J. Kennedy, P. Langmuir, R. B. Natale, R. S. Herbst, B. E. Johnson, and J. V. Heymach
Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer
Clin. Cancer Res.,
May 15, 2009;
15(10):
3600 - 3609.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. N. Armaiz-Pena, L. S. Mangala, W. A. Spannuth, Y. G. Lin, N. B. Jennings, A. M. Nick, R. R. Langley, R. Schmandt, S. K. Lutgendorf, S. W. Cole, et al.
Estrous Cycle Modulates Ovarian Carcinoma Growth
Clin. Cancer Res.,
May 1, 2009;
15(9):
2971 - 2978.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist,
May 1, 2009;
14(5):
478 - 488.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. N. Jackson, L. A. Chen, S. D. Larson, S. R. Silva, P. G. Rychahou, P. J. Boor, J. Li, G. DeFreitas, W. L. Stafford, C. M. Townsend Jr., et al.
Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Clin. Cancer Res.,
April 15, 2009;
15(8):
2747 - 2755.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Birmingham, J. V. Busik, F. M. Hansen-Smith, and J. I. Fenton
Novel mechanism for obesity-induced colon cancer progression
Carcinogenesis,
April 1, 2009;
30(4):
690 - 697.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zhu, Y. Ou, Y. Li, R. Xiao, M. Shu, Y. Zhou, J. Xie, S. He, P. Qiu, and G. Yan
A Small-Molecule Triptolide Suppresses Angiogenesis and Invasion of Human Anaplastic Thyroid Carcinoma Cells via Down-Regulation of the Nuclear Factor-{kappa}B Pathway
Mol. Pharmacol.,
April 1, 2009;
75(4):
812 - 819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. W. Ma and A. A. Adjei
Novel Agents on the Horizon for Cancer Therapy
CA Cancer J Clin,
March 1, 2009;
59(2):
111 - 137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Knopp, C Trope, J M Nesland, and R Holm
A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice
J. Clin. Pathol.,
March 1, 2009;
62(3):
212 - 218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Brunet-Dunand, C. Vouyovitch, S. Araneda, V. Pandey, L. J.-P. Vidal, C. Print, H. C. Mertani, P. E. Lobie, and J. K. Perry
Autocrine Human Growth Hormone Promotes Tumor Angiogenesis in Mammary Carcinoma
Endocrinology,
March 1, 2009;
150(3):
1341 - 1352.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Inuzuka, M. Tsuda, S. Tanaka, H. Kawaguchi, Y. Higashi, and Y. Ohba
Integral Role of Transcription Factor 8 in the Negative Regulation of Tumor Angiogenesis
Cancer Res.,
February 15, 2009;
69(4):
1678 - 1684.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J. Burstein, Y.-H. Chen, L. M. Parker, J. Savoie, J. Younger, I. Kuter, P. D. Ryan, J. E. Garber, H. Chen, S. M. Campos, et al.
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Clin. Cancer Res.,
December 1, 2008;
14(23):
7871 - 7877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis
JAMA,
November 19, 2008;
300(19):
2277 - 2285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Schultheis, G. Lurje, K. E. Rhodes, W. Zhang, D. Yang, A. A. Garcia, R. Morgan, D. Gandara, S. Scudder, A. Oza, et al.
Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
Clin. Cancer Res.,
November 15, 2008;
14(22):
7554 - 7563.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. Kesmodel, L. M. Ellis, E. Lin, G. J. Chang, E. K. Abdalla, S. Kopetz, J.-N. Vauthey, M. A. Rodriguez-Bigas, S. A. Curley, and B. W. Feig
Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases
J. Clin. Oncol.,
November 10, 2008;
26(32):
5254 - 5260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Ellis and D. J. Hicklin
Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy
Clin. Cancer Res.,
October 15, 2008;
14(20):
6371 - 6375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Lurje, W. Zhang, A. M. Schultheis, D. Yang, S. Groshen, A. E. Hendifar, H. Husain, M. A. Gordon, F. Nagashima, H. M. Chang, et al.
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer
Ann. Onc.,
October 1, 2008;
19(10):
1734 - 1741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Willmann, Z. Cheng, C. Davis, A. M. Lutz, M. L. Schipper, C. H. Nielsen, and S. S. Gambhir
Targeted Microbubbles for Imaging Tumor Angiogenesis: Assessment of Whole-Body Biodistribution with Dynamic Micro-PET in Mice
Radiology,
October 1, 2008;
249(1):
212 - 219.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Anderson, N. E. Hastings, B. R. Blackman, and R. J. Price
Capillary Sprout Endothelial Cells Exhibit a CD36low Phenotype: Regulation by Shear Stress and Vascular Endothelial Growth Factor-Induced Mechanism for Attenuating Anti-Proliferative Thrombospondin-1 Signaling
Am. J. Pathol.,
October 1, 2008;
173(4):
1220 - 1228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Fan, M. J. Gray, N. A. Dallas, A. D. Yang, G. Van Buren II, E. R. Camp, and L. M. Ellis
Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells
Mol. Cancer Ther.,
September 1, 2008;
7(9):
3064 - 3070.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Willmann, A. M. Lutz, R. Paulmurugan, M. R. Patel, P. Chu, J. Rosenberg, and S. S. Gambhir
Dual-targeted Contrast Agent for US Assessment of Tumor Angiogenesis in Vivo
Radiology,
September 1, 2008;
248(3):
936 - 944.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Nasti, A. Ottaiano, V. Rosario Iaffaioli, M. Berretta, and P. Delrio
Trials on Preoperative Chemotherapy in Resectable Colorectal Liver Metastases Need Prospective Evaluation of Predictive Factors of Response
J. Clin. Oncol.,
August 1, 2008;
26(22):
3812 - 3813.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Chang, I. Rizvi, N. Solban, and T. Hasan
In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment
Clin. Cancer Res.,
July 1, 2008;
14(13):
4146 - 4153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Siegel, E. I. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, J. J. Knox, H. Chen, S. Clark-Garvey, A. Weinberg, J. Mandeli, et al.
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
J. Clin. Oncol.,
June 20, 2008;
26(18):
2992 - 2998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Steeghs, H. Gelderblom, J. o. t Roodt, O. Christensen, P. Rajagopalan, M. Hovens, H. Putter, T. J. Rabelink, and E. de Koning
Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
Clin. Cancer Res.,
June 1, 2008;
14(11):
3470 - 3476.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Cai and X. Chen
Multimodality Molecular Imaging of Tumor Angiogenesis
J. Nucl. Med.,
June 1, 2008;
49(Suppl_2):
113S - 128S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Kerbel
Tumor Angiogenesis
N. Engl. J. Med.,
May 8, 2008;
358(19):
2039 - 2049.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sarkar, D. Chakroborty, U. R. Chowdhury, P. S. Dasgupta, and S. Basu
Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models
Clin. Cancer Res.,
April 15, 2008;
14(8):
2502 - 2510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kowanetz and N. Ferrara
Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective
Am. Assoc. Cancer Res. Educ. Book,
April 12, 2008;
2008(1):
173 - 181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M Ellis
Resistance to Anti-VEGF Therapy
Am. Assoc. Cancer Res. Educ. Book,
April 12, 2008;
2008(1):
203 - 207.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Bilchik and J. R. Hecht
Perioperative Risks of Bevacizumab and Other Biologic Agents for Hepatectomy: Theoretical or Evidence Based?
J. Clin. Oncol.,
April 10, 2008;
26(11):
1786 - 1788.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Sini, I. Samarzija, F. Baffert, A. Littlewood-Evans, C. Schnell, A. Theuer, S. Christian, A. Boos, H. Hess-Stumpp, J. A. Foekens, et al.
Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
Cancer Res.,
March 1, 2008;
68(5):
1581 - 1592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Willmann, K. Chen, H. Wang, R. Paulmurugan, M. Rollins, W. Cai, D. S. Wang, I. Y. Chen, O. Gheysens, M. Rodriguez-Porcel, et al.
Monitoring of the Biological Response to Murine Hindlimb Ischemia With 64Cu-Labeled Vascular Endothelial Growth Factor-121 Positron Emission Tomography
Circulation,
February 19, 2008;
117(7):
915 - 922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Salvador, B. Li, R. Hansen, D. E. Cramer, M. Kong, and J. Yan
Yeast-Derived {beta}-Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models
Clin. Cancer Res.,
February 15, 2008;
14(4):
1239 - 1247.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. X. Zhu, N. S. Holalkere, A. Muzikansky, K. Horgan, and D. V. Sahani
Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma
Oncologist,
February 1, 2008;
13(2):
120 - 125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Willmann, R. Paulmurugan, K. Chen, O. Gheysens, M. Rodriguez-Porcel, A. M. Lutz, I. Y. Chen, X. Chen, and S. S. Gambhir
US Imaging of Tumor Angiogenesis with Microbubbles Targeted to Vascular Endothelial Growth Factor Receptor Type 2 in Mice
Radiology,
February 1, 2008;
246(2):
508 - 518.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Gray, G. Van Buren, N. A. Dallas, L. Xia, X. Wang, A. D. Yang, R. J. Somcio, Y. G. Lin, S. Lim, F. Fan, et al.
Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver
J Natl Cancer Inst,
January 16, 2008;
100(2):
109 - 120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Calvani, D. Trisciuoglio, C. Bergamaschi, R. H. Shoemaker, and G. Melillo
Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells
Cancer Res.,
January 1, 2008;
68(1):
285 - 291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Blansfield, D. Caragacianu, H. R. Alexander III, M. A. Tangrea, S. Y. Morita, D. Lorang, P. Schafer, G. Muller, D. Stirling, R. E. Royal, et al.
Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy
Clin. Cancer Res.,
January 1, 2008;
14(1):
270 - 280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Bunn Jr., E. B. Haura, and J. V. Heymach
Emerging Therapies for Non-small Cell Lung Cancer
ASCO Educational Book,
January 1, 2008;
2008(1):
e5 - e14.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Schomber, L. Kopfstein, V. Djonov, I. Albrecht, V. Baeriswyl, K. Strittmatter, and G. Christofori
Placental Growth Factor-1 Attenuates Vascular Endothelial Growth Factor-A Dependent Tumor Angiogenesis during {beta} Cell Carcinogenesis
Cancer Res.,
November 15, 2007;
67(22):
10840 - 10848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Halder, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, T. Honda, A. A. Kamat, L. Y. Han, T. J. Kim, C. Lu, et al.
Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma
Cancer Res.,
November 15, 2007;
67(22):
10976 - 10983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Donnem, S. Al-Saad, K. Al-Shibli, M. P. Delghandi, M. Persson, M. N. Nilsen, L.-T. Busund, and R. M. Bremnes
Inverse Prognostic Impact of Angiogenic Marker Expression in Tumor Cells versus Stromal Cells in Non Small Cell Lung Cancer
Clin. Cancer Res.,
November 15, 2007;
13(22):
6649 - 6657.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. Al-Dissi, D. M. Haines, B. Singh, and B. A. Kidney
Immunohistochemical Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Associated with Tumor Cell Proliferation in Canine Cutaneous Squamous Cell Carcinomas and Trichoepitheliomas
Vet. Pathol.,
November 1, 2007;
44(6):
823 - 830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
J. Clin. Oncol.,
October 20, 2007;
25(30):
4714 - 4721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Slongo, B. Molena, A. M. Brunati, M. Frasson, M. Gardiman, M. Carli, G. Perilongo, A. Rosolen, and M. Onisto
Functional VEGF and VEGF receptors are expressed in human medulloblastomas
Neuro-oncol,
October 1, 2007;
9(4):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Loberg, C. Ying, M. Craig, L. L. Day, E. Sargent, C. Neeley, K. Wojno, L. A. Snyder, L. Yan, and K. J. Pienta
Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo
Cancer Res.,
October 1, 2007;
67(19):
9417 - 9424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Emlet, K. A. Brown, D. L. Kociban, A. A. Pollice, C. A. Smith, B. B. L. Ong, and S. E. Shackney
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines
Mol. Cancer Ther.,
October 1, 2007;
6(10):
2664 - 2674.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Jost, C. Maillard, J. Lecomte, V. Lambert, M. Tjwa, P. Blaise, M.-L. Alvarez Gonzalez, K. Bajou, S. Blacher, P. Motte, et al.
Tumoral and Choroidal Vascularization: Differential Cellular Mechanisms Involving Plasminogen Activator Inhibitor Type I
Am. J. Pathol.,
October 1, 2007;
171(4):
1369 - 1380.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gridelli, P. Maione, A. Rossi, and F. De Marinis
The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments
Oncologist,
October 1, 2007;
12(10):
1183 - 1193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Youssoufian, D. J. Hicklin, and E. K. Rowinsky
Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5544s - 5548s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Wang, S. Banerjee, D. Kong, Y. Li, and F. H. Sarkar
Down-regulation of Forkhead Box M1 Transcription Factor Leads to the Inhibition of Invasion and Angiogenesis of Pancreatic Cancer Cells
Cancer Res.,
September 1, 2007;
67(17):
8293 - 8300.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Geretti, A. Shimizu, P. Kurschat, and M. Klagsbrun
Site-directed Mutagenesis in the B-Neuropilin-2 Domain Selectively Enhances Its Affinity to VEGF165, but Not to Semaphorin 3F
J. Biol. Chem.,
August 31, 2007;
282(35):
25698 - 25707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Elser, L. L. Siu, E. Winquist, M. Agulnik, G. R. Pond, S. F. Chin, P. Francis, R. Cheiken, J. Elting, A. McNabola, et al.
Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma
J. Clin. Oncol.,
August 20, 2007;
25(24):
3766 - 3773.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Van Buren II, A. Rashid, A. D. Yang, E. K. Abdalla, M. J. Gray, W. Liu, R. Somcio, F. Fan, E. R. Camp, J. C. Yao, et al.
The Development and Characterization of a Human Midgut Carcinoid Cell Line
Clin. Cancer Res.,
August 15, 2007;
13(16):
4704 - 4712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Gollob, W. K. Rathmell, T. M. Richmond, C. B. Marino, E. K. Miller, G. Grigson, C. Watkins, L. Gu, B. L. Peterson, and J. J. Wright
Phase II Trial of Sorafenib Plus Interferon Alfa-2b As First- or Second-Line Therapy in Patients With Metastatic Renal Cell Cancer
J. Clin. Oncol.,
August 1, 2007;
25(22):
3288 - 3295.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. O. Hanrahan and J. V. Heymach
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Clin. Cancer Res.,
August 1, 2007;
13(15):
4617s - 4622s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang, and D. P. Carbone
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF
Blood,
July 15, 2007;
110(2):
624 - 631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. V. Dickson, J. B. Hamner, T. L. Sims, C. H. Fraga, C. Y.C. Ng, S. Rajasekeran, N. L. Hagedorn, M. B. McCarville, C. F. Stewart, and A. M. Davidoff
Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy
Clin. Cancer Res.,
July 1, 2007;
13(13):
3942 - 3950.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. Gendreau, R. Ventura, P. Keast, A. D. Laird, F. M. Yakes, W. Zhang, F. Bentzien, B. Cancilla, J. Lutman, F. Chu, et al.
Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647
Clin. Cancer Res.,
June 15, 2007;
13(12):
3713 - 3723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Peters, S. Julien, P. Heiduschka, S. Grisanti, F. Ziemssen, M. Adler, U. Schraermeyer, K.-U. Bartz-Schmidt, and the Tuebingen Bevacizumab Study Group
Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells
Br J Ophthalmol,
June 1, 2007;
91(6):
827 - 831.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Langley and I. J. Fidler
Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis
Endocr. Rev.,
May 1, 2007;
28(3):
297 - 321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Tang, Q. Zhang, J. Nishitani, J. Brown, S. Shi, and A. D. Le
Overexpression of Human Papillomavirus Type 16 Oncoproteins Enhances Hypoxia-Inducible Factor 1{alpha} Protein Accumulation and Vascular Endothelial Growth Factor Expression in Human Cervical Carcinoma Cells
Clin. Cancer Res.,
May 1, 2007;
13(9):
2568 - 2576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R.J. Carlson, W. B. Pope, S. Horvath, J. G. Braunstein, P. Nghiemphu, C.-L. Tso, I. Mellinghoff, A. Lai, L. M. Liau, P. S. Mischel, et al.
Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2
Clin. Cancer Res.,
May 1, 2007;
13(9):
2592 - 2598.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Alarcon and K. M Page
Mathematical models of the VEGF receptor and its role in cancer therapy
J R Soc Interface,
April 22, 2007;
4(13):
283 - 304.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kong, Y. Li, Z. Wang, S. Banerjee, and F. H. Sarkar
Inhibition of Angiogenesis and Invasion by 3,3'-Diindolylmethane Is Mediated by the Nuclear Factor-{kappa}B Downstream Target Genes MMP-9 and uPA that Regulated Bioavailability of Vascular Endothelial Growth Factor in Prostate Cancer
Cancer Res.,
April 1, 2007;
67(7):
3310 - 3319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Senan and E. F. Smit
Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy
Oncologist,
April 1, 2007;
12(4):
465 - 477.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gridelli, P. Maione, F. Del Gaizo, G. Colantuoni, C. Guerriero, C. Ferrara, D. Nicolella, D. Comunale, A. De Vita, and A. Rossi
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
Oncologist,
February 1, 2007;
12(2):
191 - 200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Dome, M. J.C. Hendrix, S. Paku, J. Tovari, and J. Timar
Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications
Am. J. Pathol.,
January 1, 2007;
170(1):
1 - 15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Korpanty, J. G. Carbon, P. A. Grayburn, J. B. Fleming, and R. A. Brekken
Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature
Clin. Cancer Res.,
January 1, 2007;
13(1):
323 - 330.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Wang, H. Wang, Y. Guo, W. Ning, S. Katkuri, W. Wahli, B. Desvergne, S. K. Dey, and R. N. DuBois
From the Cover: Crosstalk between peroxisome proliferator-activated receptor {delta} and VEGF stimulates cancer progression
PNAS,
December 12, 2006;
103(50):
19069 - 19074.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Yasuda, K. Nakayama, M. Watanabe, S. Suzuki, H. Fuji, S. Okinaga, A. Kanda, K. Zayasu, T. Sasaki, M. Asada, et al.
Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma.
Clin. Cancer Res.,
November 15, 2006;
12(22):
6748 - 6757.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-C. Liu, T. Zhang, H. Fukuhara, T. Kuroda, T. Todo, X. Canron, A. Bikfalvi, R. L. Martuza, A. Kurtz, and S. D. Rabkin
Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors.
Clin. Cancer Res.,
November 15, 2006;
12(22):
6791 - 6799.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Cai, J. Rao, S. S. Gambhir, and X. Chen
How molecular imaging is speeding up antiangiogenic drug development.
Mol. Cancer Ther.,
November 1, 2006;
5(11):
2624 - 2633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wu, Z. Zhong, J. Huber, R. Bassi, B. Finnerty, E. Corcoran, H. Li, E. Navarro, P. Balderes, X. Jimenez, et al.
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Clin. Cancer Res.,
November 1, 2006;
12(21):
6573 - 6584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Pastorino, C. Brignole, D. Di Paolo, B. Nico, A. Pezzolo, D. Marimpietri, G. Pagnan, F. Piccardi, M. Cilli, R. Longhi, et al.
Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy.
Cancer Res.,
October 15, 2006;
66(20):
10073 - 10082.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Heidemann, D G Binion, W Domschke, and T Kucharzik
Antiangiogenic therapy in human gastrointestinal malignancies.
Gut,
October 1, 2006;
55(10):
1497 - 1511.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.A. Goodlad, A.J. Ryan, S.R. Wedge, I.T. Pyrah, D. Alferez, R. Poulsom, N.R. Smith, N. Mandir, A.J. Watkins, and R.W. Wilkinson
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer
Carcinogenesis,
October 1, 2006;
27(10):
2133 - 2139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S M Hyder
Sex-steroid regulation of vascular endothelial growth factor in breast cancer.
Endocr. Relat. Cancer,
September 1, 2006;
13(3):
667 - 687.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|